The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
India in the Changing Landscape of Life-Sciences Research & Development
The company also reported significant progress toward its internally defined Sustainable Development Goals
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
Subscribe To Our Newsletter & Stay Updated
